Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-15T23:32:31.999Z Has data issue: false hasContentIssue false
  • English
  • Français

Adherence to Treatment and Therapeutic Strategies in Schizophrenic Patients: The ADHERE Study

Published online by Cambridge University Press:  07 November 2014

José Ramón Gutiérrez-Casares ,
Fernando Cañas ,
David Alonso-Escolano ,
Rebeca Hidalgo-Borrajo  and
Alexander Rodríguez-Morales
José Ramón Gutiérrez-Casares*
Affiliation:
Complejo Hospitalario Universitario de Badajoz
Fernando Cañas
Affiliation:
Hospital Rodríguez Lafora
David Alonso-Escolano
Affiliation:
Janssen-Cilag Spain
*
José Ramón Gutiérrez-Casares, MD, Hospital Infanta Cristina Avda. de Elvas s/n, 06080 Badajoz, Spain; Tel: 34-650-944-021, Fax:, 34-924-24-11-53; E-mail:, jrgutierrezcasares@gmail.com.
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim: To assess the degree of compliance and adherence to treatment during the follow-up of schizophrenic outpatients after a new therapeutic strategy had been initiated.

Methods: A multicenter, retrospective, prospective, observational study of 1,848 outpatients with schizophrenia or schizoaffective disorders (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) was conducted. Patients were treated either with oral or injectable conventional or second generation antipsychotics, and were followed up for 3 months at mental health centers. Patient compliance with the pharmacological treatment was assessed by the use of questionnaires, scales, medication accountability, and the Medication Event Monitoring System. Patients were considered compliant if they reported a high compliance rate (≥80%).

Results: At baseline only 29% of patients on oral medication were compliant compared with 79% of patients on injectable medication (injection counting) (OR= 9.11; 95% CI 6.02-13.77; P<.0001). At the 3 month visit, 84% of patients had changed their treatment and in these, the compliance rate of those on injectable medication was 94% versus 87% of patients taking oral medication (OR= 2.47; 95% CI 1.21-5.05; P=.022).

Conclusion: The use of long-acting injectable antipsychotics, which improves compliance rates and patient follow-up, should facilitate the management of Spanish patients with schizophrenia in mental health centers.

Type
Original Research
Information
CNS Spectrums , Volume 15 , Issue 5 , May 2010 , pp. 327 - 338
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Carulla, S, Ochoa, M, eds. Cumplimiento terapéutico, el gran reto de la medicina del siglo XXI. Barcelona, Spain: STM Editores; 2002.Google Scholar
2.Baca, EB, Cañas, F, Leal, C, Salvador, L, Badia, X, Alagón, Y. Análisis coste-efectividad de risperidona inyectable de larga duración vs. olanzapina y vs decanoato de flufenazina en el tratamiento de la esquizofrenia. Rev Esp Econ Salud. 2005;4:273–285.Google Scholar
3.Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886–891.CrossRefGoogle ScholarPubMed
4.Dunayevich, E, Ascher-Svanum, H, Zhao, F, et al.Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68:1163–1171.CrossRefGoogle ScholarPubMed
5.Cramer, JA, Rosenheck, R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49:196–201.CrossRefGoogle ScholarPubMed
6.Leucht, S, Heres, S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):3–8.Google ScholarPubMed
7.Perkins, DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121–1128.CrossRefGoogle ScholarPubMed
8.National Institute of Mental Health. Research on adherence to interventions for mental disorders. Bethesda, MD: National Institute of Mental Health; 1999:1–16.Google Scholar
9.Osterberg, L, Blaschke, T. Adherence to medication. N Engl J Med. 2005;353:487–497.CrossRefGoogle ScholarPubMed
10.Gilbert, PL, Harris, MJ, McAdams, LA, Jeste, DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995;52:173–188.CrossRefGoogle ScholarPubMed
11.Herings, RM, Erkens, JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12:423–424.CrossRefGoogle ScholarPubMed
12.Terkelsen, KG, Menikoff, A. Measuring the costs of schizophrenia. Implications for the post-institutional era in the US. Pharmacoeconomics. 1995;8:199–222.CrossRefGoogle ScholarPubMed
13.Weiden, PJ, Olfson, M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21:419–429.CrossRefGoogle ScholarPubMed
14.Ayuso-Gutierrez, JL, del Rio Vega, JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28:199–206.CrossRefGoogle ScholarPubMed
15.Roca, M, Canas, FOlivares, J, Rodríguez, A, Giner, J. Treatment adherence in schizophrenia. Spanish Clinical Consensus. Actas Esp Psiquiatr. 2007;35:1–6.Google ScholarPubMed
16.Chue, P, Emsley, R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs. 2007;21:441–448.CrossRefGoogle ScholarPubMed
17.Colom, F, Vieta, E, Reinares, M, et al.Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry. 2003;64:1101–1105.CrossRefGoogle ScholarPubMed
18.Novak-Grubic, V, Tavcar, R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiatry. 2002;17:148–154.CrossRefGoogle ScholarPubMed
19.Lieberman, JA, Stroup, TS, McEvoy, JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.CrossRefGoogle ScholarPubMed
20.Santarlasci, B, Messori, A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother. 2003;37:556–563.CrossRefGoogle ScholarPubMed
21.Kemmler, G, Hummer, M, Widschwendter, C, Fleischhacker, WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62:1305–1312.CrossRefGoogle ScholarPubMed
22.Gilbody, SM, Bagnall, AM, Duggan, L, Tuunainen, A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000;3:CD002306.Google Scholar
23.Byerly, MJ, Nakonezny, PA, Lescouflair, E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am. 2007;30:437–452.CrossRefGoogle ScholarPubMed
24.Kane, JM. Treatment adherence and long-term outcomes. CNS Spectr. 2007;12(Suppl 17):21–26.CrossRefGoogle ScholarPubMed
25.Rainer, MK. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat. 2008;4:919–927.CrossRefGoogle ScholarPubMed
26.Olfson, M, Mechanic, D, Hansell, S, Boyer, CA, Walkup, J, Weiden, PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv. 2000;51:216–222.CrossRefGoogle ScholarPubMed
27.Knapp, M, King, D, Pugner, K, Lapuerta, P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509–516.CrossRefGoogle ScholarPubMed
28.Gilmer, TP, Dolder, CR, Lacro, JP, et al.Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692–699.CrossRefGoogle ScholarPubMed
29.Mahmoud, RA, Stevens, MC, Meredith, C, Lee, DM, Engelhatt, LA, and the Risperidone Outcome Study & Effectiveness Group. Risperidone vs. Conventional Antipsychotics: A Prospective Randomized Naturalistic Effectiveness Trial of Outcomes in Chronic Schizophrenia. Poster presented at: the 36th Annual Meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Kamuela, Hawaii.Google Scholar
30.Dolder, CR, Lacro, JP, Dunn, LB, Jeste, DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159:103–108.CrossRefGoogle Scholar
31.Mullins, CD, Obeidat, NA, Cuffel, BJ, Naradzay, J, Loebel, AD. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2008;98:8–15.CrossRefGoogle ScholarPubMed
32.Csernansky, JG, Schuchart, EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002;16:473–484.CrossRefGoogle ScholarPubMed
33.Falloon, I, Watt, DC, Shepherd, M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med. 1978;8:59–70.CrossRefGoogle ScholarPubMed
34.Kane, JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr. 2006;11(Suppl 14):1–7.CrossRefGoogle ScholarPubMed
35.Jann, MW, Ereshefsky, L, Saklad, SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet. 1985;10:315–333.CrossRefGoogle ScholarPubMed
36.McEvoy, JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(Suppl 5): 15–18.Google ScholarPubMed
37.Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909.CrossRefGoogle ScholarPubMed
38.Thompson, K, Kulkami, J, Sergejew, AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241–247.CrossRefGoogle ScholarPubMed
39.Hogan, TP, Awad, AG, Eastwood, R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183.CrossRefGoogle ScholarPubMed
40.Remington, G, Kwon, J, Collins, A, Laporte, D, Mann, S, Christensen, B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007;90:229–237.CrossRefGoogle ScholarPubMed
41.Freudenreich, O, Cather, C, Evins, AE, Henderson, DC, Goff, DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004;65:1372–1376.CrossRefGoogle ScholarPubMed
42.Morisky, DE, Green, LW, Levine, DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.CrossRefGoogle ScholarPubMed
43.Perkins, DO. Adherence to antipsychotic medications. J Clin Psychiatry. 1999;60(Suppl 2)11:25–30.Google ScholarPubMed
44.Byerly, MJ, Nakonezny, PA, Lescouflair, E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am. 2007;30:437–452.CrossRefGoogle ScholarPubMed
45.Olivares, JM, Rodriguez-Martinez, A, Buron, JA, Alonso-Escolano, D, Rodriguez-Morales, A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6:41–53.CrossRefGoogle ScholarPubMed
46.Acosta, FJ, Bosch, E, Sarmiento, G, Juanes, N, Caballero-Hidalgo. A, Mayans, T. Evaluation of noncompliance in schizophrenia patients using electronic monitoring |MEMS(R)) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res. 2009;107:213–217.CrossRefGoogle ScholarPubMed
47.Heyscue, BE, Levin, GM, Merrick, JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv. 1998;49:1232–1234.CrossRefGoogle ScholarPubMed
48.Byerly, MJ, Nakonezny, PA, Bettcher, BM, Carmody, T, Fisher, R, Rush, AJ. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res. 2006;86:244–250.CrossRefGoogle ScholarPubMed
49.Kane, JM, Borenstein, M. Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull. 1985;21:23–27.Google ScholarPubMed
50.Hui, CL, Chen, EY, Kan, CS, Yip, KC, Law, CW, Chiu, CP. Detection of non-adherent behaviour in early psychosis. Aust N Z J Psychiatry. 2006;40:446–451.CrossRefGoogle ScholarPubMed
51.Byerly, M, Fisher, R, Whatley, K, et al.A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133:129–133.CrossRefGoogle ScholarPubMed
52.Velligan, DI, Lam, YW, Glahn, DC, et al.Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32:724–742.CrossRefGoogle ScholarPubMed
53.Straka, RJ, Fish, JT, Benson, SR, Suh, JT. Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease. J Clin Pharmacol. 1996;36:587–594.CrossRefGoogle ScholarPubMed
54.Kraus, MR, Schafer, A, Csef, H, Faller, H, Mork, H, Scheurlen, M. Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci. 2001;46:2060–2065.CrossRefGoogle ScholarPubMed
55.Waterhouse, DM, Calzone, KA, Mele, C. Brenner, DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189–1197.CrossRefGoogle ScholarPubMed
56.Herbeck, DM, Fitek, DJ, Svikis, DS, Montoya, ID, Marcus, SC, West, JC. Treatment compliance in patients with comorbid psychiatric and substance use disorders. Am J Addict. 2005;14:195–207.CrossRefGoogle ScholarPubMed
57.Tyrer, P, Mulder, R. Management of complex and severe personality disorders in community mental health services. Curr Opin Psychiatry. 2006;19:400–404.CrossRefGoogle ScholarPubMed
58.Babiker, IE. Noncompliance in schizophrenia. Psychiatr Dev. 1986;4:329–337.Google ScholarPubMed
59.Llorca, PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008;161:235–247.CrossRefGoogle ScholarPubMed
60.Weiden, PJ, Zygmunt, A. Medication noncompliance in schizophrenia. Part I Assessment. Journal of Practical Psychiatry and Behavior Health. 1997;3:106–110.Google Scholar
61.Diaz, E, Levine, HB, Sullivan, MC, et al.Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci. 2001;26:325–329.Google ScholarPubMed
62.Fleischhacker, WW, Oehl, MA, Hummer, M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry. 2003;64(Suppl 16):10–13.Google ScholarPubMed
63.Almond, S, Knapp, M, Francois, C, Toumi, M, Brugha, T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346–351.CrossRefGoogle ScholarPubMed
64.Robinson, DG, Woerner, MG, Alvir, JM, Bilder, RM, Hinrichsen, GA, Lieberman, JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57:209–219.CrossRefGoogle ScholarPubMed
65.Voruganti, L, Cortese, L, Oyewumi, L, Cernovsky, Z, Zirul, S, Awad, A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:135–145.CrossRefGoogle ScholarPubMed
66.Wirshing, DA, Pierre, JM, Erhart, SM, Boyd, JA. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am. 2003;26:165–190.CrossRefGoogle ScholarPubMed
67.Keith, SJ, Kane, JM, Turner, M, Conley, RR, Nasrallah, HA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry. 2004;65:120–131.Google ScholarPubMed
68.Lehman, AF, Lieberman, JA, Dixon, LB, et al.Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161 (Suppl 2):1–56.Google ScholarPubMed
69.Garavan, J, Browne, S, Gervin, M, Lane, A, Larkin, C, O'Callaghan, E. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry. 1998;39:215–219.CrossRefGoogle ScholarPubMed
70.Kane, JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):9–14.Google ScholarPubMed
71.Nasrallah, HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115:260–267.CrossRefGoogle ScholarPubMed
72.Schooler, NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;64(Suppl 16):14–17.Google ScholarPubMed
73.Klingberg, S, Schneider, S, Wittorf, A, Buchkremer, G, Wiedemann, G. Collaboration in outpatient antipsychotic drug treatment: Analysis of potentially influencing factors. Psychiatry Res. 2008;161:225–234.CrossRefGoogle ScholarPubMed
74.Masand, PS, Narasimhan, M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol. 2006;1:47–56.CrossRefGoogle ScholarPubMed
75.Weiden, P, Glazer, W. Assessment and treatment selegtion for “revolving door” inpatients with schizophrenia. Psychiatr Q. 1997;68:377–392.CrossRefGoogle ScholarPubMed
76.Agarwal, MR, Sharma, VK, Kishore Kumar, KV, Lowe, D. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry. 1998;44:92–106.CrossRefGoogle ScholarPubMed
77.McCann, TV, Baird, J, Clark, E, Lu, S. Mental health professionals' attitudes towards consumer participation in inpatient units. J Psychiatr Ment Health Nurs. 2008;15:10–16.CrossRefGoogle ScholarPubMed